Dose Adjustment of Subcutaneous IgG in Chronic Inflammatory Demyelinating Polyneuropathy

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an immune-mediated neuropathy that is characterized by a slowly progressive sensory and motor involvement lasting at least 2 months. We present a CIDP patient on subcutaneous Ig (SCIg). Upon fine-tuning his dose from 24 to 28 g/week...

Descripción completa

Detalles Bibliográficos
Autores principales: Alsolaihim, Alanood, Baker, Steven K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2020
Materias:
Single Case − General Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098347/
https://www.ncbi.nlm.nih.gov/pubmed/32231547
http://dx.doi.org/10.1159/000505320
_version_ 1783511165428563968
author Alsolaihim, Alanood
Baker, Steven K.
author_facet Alsolaihim, Alanood
Baker, Steven K.
author_sort Alsolaihim, Alanood
collection PubMed
description Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an immune-mediated neuropathy that is characterized by a slowly progressive sensory and motor involvement lasting at least 2 months. We present a CIDP patient on subcutaneous Ig (SCIg). Upon fine-tuning his dose from 24 to 28 g/week, this showed a dramatic improvement in both hand grip (13–25%) and dorsiflexion (73–278%). Follow-up nerve conduction studies also demonstrated significant improvements in latencies, motor amplitudes, and conduction velocities. Ongoing surveillance of CIDP patients receiving SCIg therapy is therefore necessary to ensure therapeutic optimization.
format Online
Article
Text
id pubmed-7098347
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-70983472020-03-30 Dose Adjustment of Subcutaneous IgG in Chronic Inflammatory Demyelinating Polyneuropathy Alsolaihim, Alanood Baker, Steven K. Case Rep Neurol Single Case − General Neurology Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an immune-mediated neuropathy that is characterized by a slowly progressive sensory and motor involvement lasting at least 2 months. We present a CIDP patient on subcutaneous Ig (SCIg). Upon fine-tuning his dose from 24 to 28 g/week, this showed a dramatic improvement in both hand grip (13–25%) and dorsiflexion (73–278%). Follow-up nerve conduction studies also demonstrated significant improvements in latencies, motor amplitudes, and conduction velocities. Ongoing surveillance of CIDP patients receiving SCIg therapy is therefore necessary to ensure therapeutic optimization. S. Karger AG 2020-02-14 /pmc/articles/PMC7098347/ /pubmed/32231547 http://dx.doi.org/10.1159/000505320 Text en Copyright © 2020 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/4.0/ This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Single Case − General Neurology
Alsolaihim, Alanood
Baker, Steven K.
Dose Adjustment of Subcutaneous IgG in Chronic Inflammatory Demyelinating Polyneuropathy
title Dose Adjustment of Subcutaneous IgG in Chronic Inflammatory Demyelinating Polyneuropathy
title_full Dose Adjustment of Subcutaneous IgG in Chronic Inflammatory Demyelinating Polyneuropathy
title_fullStr Dose Adjustment of Subcutaneous IgG in Chronic Inflammatory Demyelinating Polyneuropathy
title_full_unstemmed Dose Adjustment of Subcutaneous IgG in Chronic Inflammatory Demyelinating Polyneuropathy
title_short Dose Adjustment of Subcutaneous IgG in Chronic Inflammatory Demyelinating Polyneuropathy
title_sort dose adjustment of subcutaneous igg in chronic inflammatory demyelinating polyneuropathy
topic Single Case − General Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098347/
https://www.ncbi.nlm.nih.gov/pubmed/32231547
http://dx.doi.org/10.1159/000505320
work_keys_str_mv AT alsolaihimalanood doseadjustmentofsubcutaneousigginchronicinflammatorydemyelinatingpolyneuropathy
AT bakerstevenk doseadjustmentofsubcutaneousigginchronicinflammatorydemyelinatingpolyneuropathy

Ejemplares similares